Does Serum Tau Protein Predict the Outcome of Patients with Ischemic Stroke?
Does Serum Tau Protein Predict the Outcome of Patients with Ischemic Stroke?
复制标题
DOI：
10.1007/s12031-010-9403-4
复制
发表时间：
2011-03-01
影响因子：
3.1
通讯作者：
Bartosik-Psujek, Halina
中科院分区：
文献类型：
--
作者：
Bielewicz, Joanna;Kurzepa, Jacek;Bartosik-Psujek, Halina
缺血性脑卒中（IS）后预后的预测目前是基于临床和放射学评估的间接数据。我们评估了血清Tau蛋白作为IS可能的预后标志物的有效性。56例经计算机断层扫描证实的IS患者入组。在中风发作后第1、3、5和10天采集血样。采用市售酶联免疫吸附法测定血清Tau和S100BB水平。在中风的第1、3、5和10天，用美国国立卫生研究院卒中量表对神经功能缺损进行量化。在中风后第1、3、5、10天及3个月用Barthel指数和Rankin量表评定功能障碍。在入院时和诊断为IS发病后第10天进行计算机断层扫描以计算梗死体积。47.8% IS患者血清中检测到Tau蛋白。血清中检测到Tau蛋白的患者与未检测到Tau蛋白的患者相比，出现更严重的神经功能缺损，IS早期和晚期功能状态更差，并且发现梗死体积更大。然而，在IS早期阶段测量的Tau蛋白浓度与IS早期和3个月后的神经功能缺陷和残疾程度无关。IS患者血清中Tau蛋白的检测而非其浓度的检测可被认为是IS早期和晚期临床结局的不良预后因素。
The prediction of outcome after ischemic stroke (IS) is currently based on indirect data from clinical and radiological evaluation. We evaluated the usefulness of serum Tau protein as possible prognostic markers for IS. Fifty-six patients with computed tomography-confirmed IS were enrolled. Blood samples were obtained on days 1, 3, 5, and 10 after stroke onset. Tau and S100BB serum levels were measured by commercially available enzyme-linked immunosorbent assay. Neurological deficits were quantified by the National Institute of Health Stroke Scale on days 1, 3, 5, and 10 of stroke. Functional disability was rated with the Barthel Index and Rankin Scale on days 1, 3, 5, and 10 and additionally 3 months after the stroke. Computed tomography scan was performed to calculate infarct volume on admission to hospital and on day 10 from the diagnosis of IS onset. Tau protein was detected in the serum of 47.8% patients with IS. Patients in whom Tau protein was detected in serum, when compared with patients without Tau protein, developed more severe neurological deficits, had worse functional status measured in the early and late phase of IS, and were found to have larger volume of infarction. However, Tau protein concentrations measured within the early phase of IS did not correlate with degrees of neurological deficit and disability in the early phase and also after 3 months of IS. Detection of Tau protein in the serum of patients with IS but not its concentration can be considered as a bad prognostic factor for the clinical outcome in early and late phase of IS.